An economic evaluation of rizatriptan in the treatment of migraine

PharmacoEconomics

Volumn 23, Issue 8, 2005, Pages 837-850

  Thompson, Melissa ^a   Gawel, Marek ^b   Desjardins, Brigitte ^c   Ferko, Nicole ^a   Grima, Daniel ^a  

^a i3 Global   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ARTICLE; CANADA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MIGRAINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

CANADA; COST-BENEFIT ANALYSIS; DECISION TREES; HUMANS; MIGRAINE DISORDERS; REPRODUCIBILITY OF RESULTS; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 26444590601     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523080-00008     Document Type: Article

References (45)

1. Lance JW, Goadsby PJ. Mechanism and management of headache. 6th ed. Boston (MA): Butterworth-Heinemann, 1998
2. Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. Oxford: Isis Medical Media, 1998
3. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002; 346 (4): 257-70
4. Martin S. Prevalence of migraine headache in Canada. Can Med Assoc J 2001; 164 (10): 1481
5. O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population based survey. Int J Epidemiol 1994; 23 (5): 1020-6
6. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Can Med Assoc J 1997; 156 (9): 1273-87
7. Oldman AD, Smith LA, McQuay HJ, et al. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002; 97: 247-57
8. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-58
9. Gawel MJ, Worthington I, Maggisano A. A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001; 28: 30-41
10. Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res 2001; 4: 105-25
11. Pfaffenrath V, Cunin G, et al. Efficacy and safety of sumatriptan tablets (25mg, 50mg, 100mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-90
12. Brogan. Ontario Drug Benefit Database, 2002
13. Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache 2002; 42: 93-8
14. Christie S, Gobel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur J Neurol 2003; 49: 20-9
15. Solomon S, Frishberg B, Hu XH, et al. Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study. Clin Ther 2001; 23: 886-96
16. Biddle AK, Shih YC, Kwong J. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 2000; 20 (11): 1356-64
17. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack. Arch Intern Med 1998; 158: 1013-8
18. Evans KW, Boan JA, Evans JL, et al. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharmacoeconomics 1997; 12 (5): 565-77
19. Davies GM, Santanello N, Gerth W, et al. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 1999; 19: 497-502
20. Dasbach EJ, Carides GW, Gerth WC, et al. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 2000; 20: 830-4
21. Laloux P, Vakaet A, Monseu G, et al. Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation. Acta Neurol Belg 1998; 98: 332-41
22. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995; 35: 449-54
23. Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Managed Care 1996; 2: 1407-16
24. Kramer MS, Matzura-Wolfe BS, Getson A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurol Clin 1998; 51: 773-81
25. Dowson AJ, MacGregor EA, Purdy RA, et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002; 22: 101-6
26. Mathew NT, Asgharnejad M, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Neurol 1997; 49: 1485-90
27. Savani N, Brautaset NJ, Reunanen M, et al. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. UCP Review 1999; Suppl 105: 7-14
28. Lambert J, Carides GW, Meloche JP, et al. Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial. Can J Clin Pharmacol 2002; 9: 158-64
29. Sieber WJ, David KM, Adams JE, et al. Assessing the impact of migraine on health-related quality of life: an additional use of the Quality of Well-Being Scale self-administered. Headache 2000; 40: 662-71
30. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765-86
31. Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurol Clin 2001; 57: 1377-83
32. Caro G, Getsios D, Caro JJ, et al. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. Cephalalgia 2001; 21: 12-9
33. Hospital Indicators 1993/94. Ottawa: Statistics Canada, 1996
34. Jacobs P, Bachynsky J, Hall E. A manual of standard cost for pharmacoeconomic studies in Canada: feasibility study. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1995
35. Optenberg S, Jacobs P, Bay K, et al. Emergency care episodes: an economic profile. J Ambul Care Manage 1995; 18: 1-12
36. The Consumer Price Index for Canada, Major Components and Special Aggregates. Statistics Canada-Catalogue no.62-001, Jan 2003
37. Statistics Canada. Organisation for Economic Co-operation and Development, Labour Force Statistics 1978-1999, Paris, 2000
38. Statistics Canada. Average Industrial Wage. February 2000. The Daily. 27 Apr 2000
39. Caro JJ, Getsios D, Raggio G, et al. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. Headache 2001; 41: 456-64
40. Statistics Canada, Catalogue No. 13-603E, No. 3. Household's unpaid work: measurement and valuation, 20 Dec 1995
41. Stephens T, Joubert N. The economic burden of mental health problems in Canada. Chronic Dis Can 2001; 22 (1): 18-23
42. Statistics Canada. Unpaid work of households. The Daily, 20 Dec 1995
43. Heywood J, Bouchard J, Cortelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings. Pharmacoeconomics 1997; 11 Suppl. 1: 11-23
44. Lipton RB, Stewart WF, Ryan RE, et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain. Arch Neurol 1998; 55: 210-7
45. Wells N, Hettiarachchi J, et al. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health 2003; 6 (4): 438-47